PrandiMet(R), First Repaglinide And Metformin HCl Fixed Dose Combination Therapy, Now Available In The United States
Novo Nordisk and Sciele Pharma, Inc., a Shionogi Company, announced the availability of PrandiMet® (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the short-acting secretagogue repaglinide (also known as Prandin®) and insulin sensitizer metformin HCl for the treatment of type 2 diabetes in the United States.
Subscribe to:
Posts (Atom)
